Northwestern Mutual Wealth Management Co. Makes New $844,000 Investment in West Pharmaceutical Services, Inc. $WST

Northwestern Mutual Wealth Management Co. bought a new stake in West Pharmaceutical Services, Inc. (NYSE:WST) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 2,350 shares of the medical instruments supplier’s stock, valued at approximately $844,000.

Several other hedge funds also recently modified their holdings of WST. Elyxium Wealth LLC bought a new stake in West Pharmaceutical Services during the fourth quarter worth $25,000. CYBER HORNET ETFs LLC bought a new position in West Pharmaceutical Services during the 2nd quarter valued at $25,000. Cornerstone Planning Group LLC boosted its holdings in West Pharmaceutical Services by 90.9% during the 1st quarter. Cornerstone Planning Group LLC now owns 105 shares of the medical instruments supplier’s stock worth $26,000 after acquiring an additional 50 shares during the last quarter. Bayban bought a new stake in shares of West Pharmaceutical Services in the 4th quarter worth $27,000. Finally, Avalon Trust Co bought a new stake in shares of West Pharmaceutical Services in the 2nd quarter worth $28,000. Hedge funds and other institutional investors own 93.90% of the company’s stock.

Analysts Set New Price Targets

WST has been the topic of a number of recent analyst reports. Evercore reissued an “outperform” rating and set a $425.00 price target on shares of West Pharmaceutical Services in a research report on Monday, July 27th. TD Cowen reaffirmed a “buy” rating on shares of West Pharmaceutical Services in a research report on Wednesday, July 15th. Zacks Research lowered shares of West Pharmaceutical Services from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 12th. BNP Paribas Exane began coverage on shares of West Pharmaceutical Services in a research report on Monday, July 13th. They set an “outperform” rating and a $447.00 target price on the stock. Finally, Weiss Ratings upgraded West Pharmaceutical Services from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $368.08.

West Pharmaceutical Services Price Performance

WST opened at $348.97 on Wednesday. West Pharmaceutical Services, Inc. has a fifty-two week low of $223.83 and a fifty-two week high of $386.00. The firm has a 50-day moving average of $349.44 and a 200 day moving average of $301.84. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.12 and a current ratio of 2.82. The firm has a market cap of $24.56 billion, a P/E ratio of 44.68, a PEG ratio of 2.47 and a beta of 1.15.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings data on Thursday, July 23rd. The medical instruments supplier reported $2.37 EPS for the quarter, topping the consensus estimate of $2.08 by $0.29. The business had revenue of $872.30 million for the quarter, compared to analyst estimates of $839.98 million. West Pharmaceutical Services had a net margin of 16.98% and a return on equity of 20.11%. The company’s revenue for the quarter was up 13.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.84 earnings per share. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. On average, research analysts expect that West Pharmaceutical Services, Inc. will post 8.93 EPS for the current year.

West Pharmaceutical Services Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, August 5th. Investors of record on Wednesday, July 29th were issued a $0.22 dividend. This represents a $0.88 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date of this dividend was Wednesday, July 29th. West Pharmaceutical Services’s payout ratio is 11.27%.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.